BRTX

BRTX

BioRestorative Therapies, Inc.

2.30 USD

Last updated Oct 7, 18:33 UTC

Yesterday HIGH

$2.29

Yesterday LOW

$2.14

52w HIGH

$34.6

52w LOW

$2.01

EPS

-2.40

PE

-0.96

Next Earnings

Oct 20, 2026

Overview News Government Trades Fundamentals

BioRestorative Therapies, Inc. stock is down -18.04% since 30 days ago. The next earnings date is Oct 20, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 29.17% of the previous 28 October’s closed higher than September. 0% of analysts rate it a buy.

Benzinga Newsdesk

Wed May 27, 2026

BioRestorative Therapies shares are trading higher after Kaos Capital announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies.
Avi Kapoor

Wed May 27, 2026

Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results

US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, energy down 1.9%. DKS stock falls 5% on mixed results.
Benzinga Newsdesk

Wed May 27, 2026

Kaos Capital Acquires 4.9% Of Issued And Outstanding Common Stock Of BioRestorative Therapies; Terms Undisclosed

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholdersMIAMI, May 27, 2026 /CNW/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist
Benzinga Newsdesk

Tue May 26, 2026

BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that the
Benzinga Insights

Tue May 19, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Newsdesk

Wed May 13, 2026

BioRestorative Therapies Presents Data Showing MSC-Derived Exosomes Have Source-Specific Functional Signatures For Targeted Therapeutic Applications At The International Society For Cell & Gene Therapy 2026 Annual Meeting

Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applicationsMELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative
Benzinga Newsdesk

Thu May 7, 2026

BioRestorative Therapies Reports 52% Of Phase 2 Patients Achieve At Least 50% Pain And Function Improvement At 52 Weeks With No Dose-Limiting Toxicity In ISCT 2026 Update

Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety
Benzinga Newsdesk

Thu Apr 30, 2026

BioRestorative Therapies To Reveal New Data At ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease And Its BioCosmeceutical Platform

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces that it
Benzinga Newsdesk

Tue Apr 21, 2026

BioRestorative Announces Strategic Partnership With David J. Goldberg, M.D. To Accelerate Market Adoption Of Its BioCosmeceutical Platform
Benzinga Newsdesk

Tue Apr 7, 2026

BioRestorative Therapies Announces Strategic Collaboration With 203 Creates To Commercialize BioRestorative's Biocosmeceutical Platform

Maxim Group

Tue Oct 6, 22:02

hold

downgrade

Advanced Data Unlock

ABBV $272.77 USD

PEP $123.80 USD

IWM $277.99 USD

UUUU $10.29 USD

WYNN $75.13 USD

SKHY SKHY $179.00 USD

CAT $811.64 USD

APLD $23.91 USD

SMCI $44.66 USD